InflaRx Achieves Significant Milestone with GOHIBIC
InflaRx N.V. (NASDAQ: IFRX), recognized for its innovative anti-inflammatory therapies, is generating excitement with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) endorsing GOHIBIC (vilobelimab) for the treatment of adult patients suffering from SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). This approval reflects a positive opinion highlighting the therapeutic significance of vilobelimab, particularly for patients requiring mechanical ventilation.
Executive Insight on the CHMP Opinion
Prof. Niels C. Riedemann, the CEO and founder of InflaRx, expressed enthusiasm about the CHMP's favorable opinion. He noted that this is a crucial step in the journey of vilobelimab, which has already received Emergency Use Authorization from the FDA. It serves as a reminder of the critical need for more effective treatments for patients suffering from severe ARDS due to COVID-19.
Importance of the Approval
The CHMP's recommendation is an indication of a favorable benefit-risk assessment for GOHIBIC. This remarkable decision comes under exceptional circumstances, acknowledging that comprehensive data for such a rare indication may not be obtainable under standard conditions. Consequently, InflaRx will commit to providing the EMA with annual updates on its clinical studies aimed at further validating the drug's efficacy.
Commercialization Plans for GOHIBIC
Looking ahead, InflaRx intends to introduce GOHIBIC in European markets under its established brand. The company is meticulously exploring potential partnerships for distribution as it ventures into this new phase. Notably, this strategy is not expected to significantly impact the company's cash burn rate, ensuring financial stability.
Clinical Studies Highlighting Vilobelimab's Efficacy
The promising opinion from CHMP aligns with data from the multicenter Phase 3 PANAMO trial, recognized as one of the largest randomized double-blind studies conducted on invasively ventilated COVID-19 patients. Findings indicated a remarkable 23.9% reduction in 28-day all-cause mortality for patients receiving vilobelimab compared to the placebo group, underscoring its potential as a life-saving treatment.
Understanding GOHIBIC: Composition and Use
Vilobelimab, classified as a first-in-class monoclonal antibody targeting human complement factor C5a, operates by blocking this inflammatory mediator's activity. While preventing the formation of harmful immune complexes, it simultaneously preserves essential components of the innate immune system. This dual action is pivotal in managing inflammation without compromising the body's defenses.
Broader Indications for Vilobelimab
Besides its application for COVID-19, vilobelimab is also being investigated for various other challenging inflammatory conditions, including pyoderma gangrenosum (PG). With orphan drug designation granted by both the FDA and EMA for PG, InflaRx showcases its commitment to addressing critical health challenges surrounding inflammatory diseases.
Contact Information and Further Resources
For inquiries regarding InflaRx and its products, please connect with:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What is GOHIBIC?
GOHIBIC (vilobelimab) is a monoclonal antibody that targets the complement factor C5a, primarily designed for severe cases of ARDS due to COVID-19.
What did the CHMP recommend for GOHIBIC?
The CHMP adopted a positive opinion recommending marketing authorization for GOHIBIC for patients with ARDS under exceptional circumstances.
How does vilobelimab function?
Vilobelimab blocks C5a, an inflammatory mediator, without compromising the innate immune response, thus controlling excessive tissue damage while preserving bodily defenses.
What was the PANAMO trial?
The PANAMO trial was a pivotal Phase 3 study showcasing vilobelimab's efficacy in reducing mortality among invasively ventilated COVID-19 patients.
What are the future plans for GOHIBIC?
InflaRx plans to commercialize GOHIBIC in Europe and continue research on its effectiveness while exploring distribution partnerships.
